<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutation of the ras oncogenes is the most commonly detected molecular abnormality in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This molecular event may either be acquired by different subclones or by <z:hpo ids='HP_0000001'>all</z:hpo> malignant cells </plain></SENT>
<SENT sid="2" pm="."><plain>The availability of the ras p21 monoclonal antibody Y13 259 makes possible the direct study of the distribution of the ras gene product in human malignant cells </plain></SENT>
<SENT sid="3" pm="."><plain>The bone marrow smears from 41 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were analysed by two independent observers after treatment with MoAb Y13 259, biotinylated goat antirat IgG, streptavidin, peroxidase and staining with diaminobenzidine </plain></SENT>
<SENT sid="4" pm="."><plain>A high proportion of strongly positive smears was found among patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>This positivity was found in 25% of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>, in 80% of the <z:hpo ids='HP_0005505'>refractory anemias</z:hpo> with excess of blasts, and in 90% of those in transformation, while <z:hpo ids='HP_0000001'>all</z:hpo> 7 cases with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> were found positive </plain></SENT>
<SENT sid="6" pm="."><plain>The percentage of positivity may suggest that activation of ras oncogene in associated with disease progression </plain></SENT>
</text></document>